The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Treatment Guidelines to Be Presented at the 2016 ACR/ARHP Annual Meeting

New Treatment Guidelines to Be Presented at the 2016 ACR/ARHP Annual Meeting

October 27, 2016 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Two sets of guidelines—one on managing anti-rheumatic drugs perioperatively for patients undergoing total hip and knee replacements, and another that updates glucocorticoid-induced osteoporosis prevention and treatment strategies—will be featured in sessions at the 2016 ACR/ARHP Annual Meeting this month.

You Might Also Like
  • New GIOP Guidelines Available
  • New Lupus Classification Criteria Presented at ACR/ARHP Annual Meeting
  • ACR/ARHP 2016 Research Conferences Foster Exchanges with Colleagues Before Annual Meeting Start
Also By This Author
  • EULAR 2015: Biology of Fatigue Rooted in Genes, Cytokines, Free Radicals

The Sessions
Sunday, Nov. 13, 2:30–3:30 p.m.: Glucocorticoid-Induced Osteoporosis Prevention and Treatment: A New ACR Clinical Guideline

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • Monday, Nov. 14, 9:00–10:00 a.m.: Perioperative Management of Anti-Rheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Knee Arthroplasty: A New ACR/AAHKS Clinical Guideline

Perioperative Management Guideline

Key Points & Current Status
Some of the points to be covered in the perioperative anti-rheumatic medication management guideline—developed by the ACR in partnership with the American Association of Hip and Knee Surgeons—include recommendations for:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  • High-risk patients, including systemic autoimmune inflammatory diseases with inflammatory arthritis and systemic lupus erythematosus;
  • The stopping and restarting of medications; and
  • The use of “rescue” medications for post-op flares.

The manuscript is now under review, says Susan Goodman, MD, the ACR co-principal investigator for the guideline and associate professor of medicine at Weill Cornell Medical College.

Infection/Biologic Concerns
She says the time is right for the introduction of these recommendations, because the increased use of disease-modifying drugs and biologics means that most patients coming in for these surgeries will be taking these medications.

“The biggest concern with knee and hip replacement surgery is the risk of infection,” Dr. Goodman says. “The [guideline] gives our recommendations on what medications to stop before surgery and what should be continued and, if stopped, when they should be restarted.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

 One of the recommendations concerns biologics.

“All of the biologic medications were found to be associated with an increased risk of infection,” she says. “Because of this and the level of importance patients place on minimizing infection risk, we’ve recommended that biologics be withheld prior to surgery.”

Glucocorticoid-Induced Osteoporosis Guideline

What’s Involved?
Lenore Buckley, MD, MPH, the principal investigator and professor of rheumatology and pediatrics at Yale University, says updating the ACR’s 2010 guidelines on glucocorticoid-induced osteoporosis prevention and management involved reexamining the benefits and harms of fracture-reduction therapies. It also involved focusing on subpopulations and the use of more finely tailored fracture-risk assessment tools that combine other osteoporosis risk factors with glucocorticoid use to generate an absolute fracture risk that aids clinicians and patients in decision making.

“The estimate is that about one in 100 adults may be on chronic glucocorticoids in the U.S. and internationally,” she says. “And they’re not just prescribed by rheumatologists; they’re prescribed by primary care physicians and many specialties for various inflammatory diseases, from severe asthma to inflammatory bowel disease to inflammatory neurologic diseases. So we think the recommendations will have a wide impact.”

Pages: 1 2 | Single Page

Filed Under: Professional Topics Tagged With: 2016 ACR/ARHP Annual Meeting, anti-rheumatic drugs, Biologics, Glucocorticoid-Induced Osteoporosis, Osteoporosis, treatment guidelines

You Might Also Like:
  • New GIOP Guidelines Available
  • New Lupus Classification Criteria Presented at ACR/ARHP Annual Meeting
  • ACR/ARHP 2016 Research Conferences Foster Exchanges with Colleagues Before Annual Meeting Start
  • 2014 ACR/ARHP Annual Meeting: Rheumatoid Arthritis Management Treatment Recommendations

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.